All In Biotech

NDA 214958 · Bristol

Sotyktu

Deucravacitinib · Oral · Tyrosine Kinase 2 Inhibitor

Novel

CDER novel approval, Sep 9, 2022: To treat moderate-to-severe plaque psoriasis

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Sep 9, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

85

21 Phase 3, 15 recruiting

FAERS reports

2,976

619 serious, 46 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 30, 2026.

SOTYKTU is a tyrosine kinase 2 (TYK2) inhibitor indicated for: • the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other potent immunosuppressants. • the treatment of active psoriatic arthritis in adults. ( 1.2 ) 1.1 Plaque Psoriasis SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : SOTYKTU is not recommended for use in combination with other potent immunosuppressants. 1.2 Psoriatic Arthritis SOTYKTU is indicated for the treatment of active psoriatic arthritis in adults.

Mechanism: Deucravacitinib is an inhibitor of tyrosine kinase 2 (TYK2). TYK2 is a member of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory and the catalytic domains of the enzyme. This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream activation of Signal Transducers and Activators of Transcription (STATs) as shown in cell-based assays. JAK kinases, including TYK2, function as pairs of homo- or heterodimers in the JAK-STAT pathways. TYK2 pairs with JAK1 to...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SOTYKTU · DEUCRAVACITINIB 6MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Deucravacitinib" as an intervention, any sponsor and status, largest first.

All 85 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective286
  • acne255
  • pruritus244
  • rash206
  • psoriasis190
  • erythema171
  • off label use120
  • skin burning sensation88
  • product dose omission issue83
  • adverse event82
  • headache82
  • pain79

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20211
2022140
20231,053
2024850
2025579
2026352

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sotyktu (Deucravacitinib)

2024 spending

$62.2M

Beneficiaries

1,803

8,580 claims

Per beneficiary

$34,513

$216.75 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,499,644
2023$34,323,077
2024$62,226,384

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 67 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.